[Pathogenesis of choroidal neovascularization. Old concepts, new questions].
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world but the pathogenesis remains poorly understood. Malfunction of the retinal pigment epithelium (RPE) plays a central role in the disease and leads to either choriodal atrophy or proliferation. This article reviews the current concepts of the development of choriodal atrophy and neovascularisation. Furthermore, available animal models and potential therapeutical targets are discussed.
Fauser
S
S
Abteilung für Netzhaut- und Glaskörperchirurgie und Zentrum für Molekulare Medizin, Universität zu Köln, Cologne. sfauser@hgmp.mrc.ac.uk
Engelmann
K
K
Krohne
T U
TU
Lappas
A
A
Kirchhof
B
B
Joussen
A M
AM
D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002478:Cells, Cultured; D020256:Choroidal Neovascularization / Q000150:complications / Q000209:etiology* / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D002833:Choroiditis / Q000150:complications; D017326:Clinical Trials, Phase III as Topic; D018849:Controlled Clinical Trials as Topic; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D005131:Eye Injuries / Q000150:complications; D000882:Haplorhini; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D053685:Laser Therapy; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D008266:Macula Lutea / Q000637:transplantation; D008268:Macular Degeneration / Q000150:complications* / Q000628:therapy; D051379:Mice; D008822:Mice, Transgenic; D009216:Myopia / Q000150:complications; D010778:Photochemotherapy; D010857:Pigment Epithelium of Eye / Q000166:cytology; D051381:Rats; D015861:Retinal Neovascularization / Q000209:etiology / Q000503:physiopathology; D012307:Risk Factors; D014221:Triamcinolone / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014221:Triamcinolone; D007371:Interferon-gamma